Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 1998

View Archived Issues

Shire: six-month highlights

New advances in antiobesity drug therapy reported by Novartis

Dopamine D3 antagonist with improved selectivity, clearance discovered at SB

Dutch academics identify free radical scavengers/xanthine oxidase inhibitors

Schering-Plough prepares arylalkylamines as neurokinin antagonists

Natural nonpeptide inhibitors of protein farnesyltransferase discovered at Merck & Co.

Chugai files for regulatory approval of maxacalcitol

Fujisawa scientists synthesize new series of vasopressin antagonists

FDA grants fast track status for CDP-571

Allelix GI drug moves into the clinic

Tularik/JT establish new collaboration to develop orphan nuclear receptor modulators

Upregulators of LDL receptor in development at Pfizer as hypocholesterolemic agents

New anticonvulsant series developed from SB-204269 at SKB

Ixion receives patent allowance for technology to treat oxalate-related disorders

Synthesis and SAR for piperidine SSNRAs reported at ACS by Parke-Davis/CoCensys

Efficacy of thiazolidinedione rosiglitazone highlighted at diabetes meeting

New T-cell kinase inhibitor presented by Abbott at ACS meeting

MMP inhibitor PGE-2946979 shows good oral antiarthritic activity in rats

Collateral Therapeutics terminates VEGF gene agreement

Exendin-4 inhibits feeding in rats, indicating potential utility for appetite control in humans

Merck's COX-2 inhibitor Vioxx shown safe and effective in clinical trials

KW-5139 effective for reducing gastric stasis following pancreatoduodenectomy

RALES study brought to an early end based on positive impact on mortality

Antisecretory and antiulcer effects of S-0509 characterized in rats

Early clinical results reported for osutidine, an H2 antagonist from Toyama

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...